New hope for kids: drug may shield against viruses after transplant
NCT ID NCT07488728
First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tests whether the drug letermovir can prevent serious viral infections in children with rare EBV-related blood diseases who receive a stem cell transplant. About 80 children will either get letermovir or standard care. The goal is to see if it reduces infections and other transplant complications like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED T/NK-CELL LYMPHOPROLIFERATIVE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.